Forecast the future of neurology across 31+ indications

DRG Disease Landscape & Forecast

Clarivate Disease Landscape & Forecast reports offer expert-driven, patient-based insights to support confident decision-making across the Central Nervous System (CNS) pipeline.

Each report covers more than 31+ neurology indications and provides in-depth forecasting, clinical development analysis, and strategic market context tailored to the needs of pharmaceutical companies, biotech innovators, and investors.

Request more information

What’s included in the reports?

  • Forecasts through 2033
    Patient-based 10-year market outlooks by indication
  • Indication-specific strategy insights
    Treatment trends, access and reimbursement, market dynamics, and more
  • Late-phase pipeline intelligence
    Stay ahead of competitors with coverage of Phase IIb/III assets and timelines
  • Expert commentary
    Interpret the data with clarity, thanks to our expert neurology analyst team including therapy area experts and neurologists.

Preview some of the oncology reports below

Sample report
Alzheimer's Disease

Sample report
Epilepsy

Sample report
Multiple Sclerosis

Covering 31+ neurology indications including:

Spinocerebellar Ataxia, Spasticityr, Progressive Supranuclear Palsy, Parkinson's Disease, Muscular Dystrophy, Multiple Sclerosis – and many more

Tailored to your needs

Whether you need insight into a single neurology disease or want a bundled view to guide portfolio planning, we’ve got you covered.

Connect with our team to explore the right options for your pipeline and commercial goals.

Request more information